This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tuomilehto, J. Articles by Leer, J. Search for Related Content PubMed PubMed Citation Articles by Tuomilehto, J. Articles by Leer, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Smoking Hazardous Substances DB METOPROLOL

Hypertension, Vol 13, 773-780, Copyright © 1989 by American Heart Association

ARTICLES

Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study

J Tuomilehto, J Wikstrand, G Olsson, D Elmfeldt, I Warnold, H Barber, K Eliasson, B Jastrup, N Karatzas and J Leer
Department of General Practice, University of Glasgow, Scotland.

The present primary prevention study aimed at investigating whether metoprolol given as initial antihypertensive treatment would lower cardiovascular complications of high blood pressure to a greater extent than thiazide diuretics. Patients were randomized to metoprolol (n = 1,609, 8,110 patient-years) or a thiazide diuretic (n = 1,625, 8,070 patient-years). At randomization, 535 patients in the metoprolol group and 524 patients in the diuretic group were classified as smokers. Blood pressure control during follow-up was equally effective regardless of smoking habits at randomization. Cardiovascular and coronary heart disease mortality was three to four times higher in smokers than in nonsmokers, underlining the importance of smoking as a risk factor. Total and cardiovascular mortality were significantly lower for the metoprolol group than for the thiazide diuretic group in the whole study population (p = 0.028 and p = 0.012), as well as in smokers (p = 0.013 and p = 0.016). Coronary heart disease mortality was significantly lower for patients on metoprolol than for patients on diuretics in the whole study population (p = 0.048) as well as in smokers (p = 0.021). The results suggest that initial antihypertensive therapy with metoprolol is associated with a lesser incidence of total, cardiovascular, and coronary heart disease mortality as compared with initial diuretic treatment, both in the whole study population and in smokers. The favorable effect of metoprolol must be mediated via mechanisms other than the blood pressure-lowering effect of metoprolol because equal blood pressure control was achieved with both types of medication, irrespective of smoking habits at randomization.

This article has been cited by other articles:

				H.L. White, A. Maqbool, A.D. McMahon, L. Yates, S.G. Ball, A.S. Hall, and A.J. Balmforth An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy Eur. Heart J., July 2, 2002; 23(14): 1087 - 1092. [Abstract] [Full Text] [PDF]

				J. A. Staessen, R. Fagard, L. Thijs, H. Celis, W. H. Birkenhager, C. J. Bulpitt, P. W. de Leeuw, A. E. Fletcher, M.-R. Babarskiene, F. Forette, et al. Subgroup and Per-Protocol Analysis of the Randomized European Trial on Isolated Systolic Hypertension in the Elderly Arch Intern Med, August 10, 1998; 158(15): 1681 - 1691. [Abstract] [Full Text]